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Abstract
Rationale: The extent to which maternal smoking in pregnancy
(MSP) has persisting effects on respiratory health remains uncertain
and themechanisms involved are not fully understood. Alterations in
immune function have been proposed as a mechanism contributing
to respiratory disease.
Objectives:To determine whetherMSP increases risk of respiratory
disorders in adolescence and, if so, whether this occurs by decreased
lung function, altered immune function, and/or enhanced atopy.
Methods:Data on spirometry, bronchial responsiveness, respiratory
symptoms, total and allergen-specific IgE and IgG4, immune
function, and inflammatory markers were obtained from 1,129
participants in the 14-year follow-up of the Western Australian
Pregnancy (Raine) Cohort and related to MSP using regression
analyses.
Measurements and Main Results:MSP was reported for 21.0%
(237 of 1,129) of participants, with 92 (8.1%) reporting current
smoking.MSPwas associatedwith some altered immunemeasures at
age 14. MSP was strongly related to reduced lung function in current
nonsmokers (forced expiratory flow midexpiratory phase
[FEF25–75%], P = 0.016; FEV1/FVC, P = 0.009) and increased risk for
current asthma (odds ratio [OR], 1.84; 95% confidence interval [CI],
1.16–2.92; P = 0.01), current wheeze (OR, 1.77; 95% CI, 1.14–2.75;
P = 0.011), and exercise-induced wheeze (OR, 2.29; 95% CI,
1.37–3.85; P = 0.002), but not for bronchial hyperresponsiveness or
atopy. Adjustment for immune measures and/or lung function in
multivariate models did not greatly alter these associations and the
increased risks for asthma and wheeze were not modified by sex,
atopy, or maternal history of asthma or atopy.
Conclusions:MSP increases risk of asthma and wheezing
in adolescence; mechanisms go beyond reducing lung
function and exclude altering immune function or enhancing
atopy.
Keywords: atopy; immune function; bronchial
hyperresponsiveness; Raine study
At a Glance Commentary
Scientific Knowledge on the Subject: The impact of
maternal smoking during pregnancy on lung function and
asthma risks in children is well known. However, how long these
effects persist and how they aremediated is not clearly understood.
What This Study Adds to the Field: The data from
the present study show that maternal smoking during
pregnancy increases risk for asthma and wheeze that persist
into adolescence independent of effects on lower lung function,
immune function, or allergic sensitization in adolescents.
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There is a great deal of evidence that
maternal smoking during pregnancy (MSP)
has detrimental effects on the health of
children, including increased body mass
index (BMI) (1–4), decreased lung function,
and increased risk for development of
asthma and wheeze (5–7). The mechanisms
underlying these effects are uncertain;
however, nicotine has reported detrimental
effects on airway development (7). Prenatal
tobacco smoke exposure is associated with
a variety of epigenetic changes affecting
gene expression, some of which are in
keeping with an asthmatic phenotype (8, 9)
and may be long lasting (8). Furthermore, it
has been suggested that MSP can impair
immune development and maturation,
processes that begin in utero and continue
after birth; these effects may modify risk for
development of respiratory disease (10).
MSP has been associated with a reduction
in allergic sensitization in some cohorts,
although there have been conflicting
findings from different studies (11).
A previous study from our laboratory
examining antenatal cytokines from 407
participants in the Western Australian
Pregnancy (Raine) longitudinal birth cohort
found that MSP was associated with lower
concentrations of IL-4 and IFN-g in cord
blood and increased risk of wheeze and
allergic sensitization at age 6 (12). This
phenotype of low Th1/Th2 cytokine
production observed in an unselected
community cohort was also seen in infants
at high genetic risk for atopy, who show
delayed maturation of T-cell competence
(13). Noakes and coworkers (14) examined
the relationship between MSP and cord
blood mononuclear cell cytokine responses
and found that IL-13 production in
response to house dust mite (HDM) or
ovalbumin was higher in infants exposed
to MSP (n = 17) than in unexposed (n = 40)
neonates. They subsequently demonstrated
in a different cohort that infants born
to mothers who smoke (n = 60) showed
significantly lower Toll-like receptor–mediated
IL-6, tumor necrosis factor, and IL-10
production but higher IFN-g production
compared with infants born to mothers
who do not smoke (n = 62) (15).
We have previous reported reduced
lung function at birth in infants from the
Raine cohort born to mothers who smoked
during pregnancy (16) and have reported
that prenatal and post-natal exposure to
tobacco smoke in these children was
associated with low lung function and
increased the risk of asthma and bronchial
hyperresponsiveness (BHR) at age 6 (17,
18). The present study was undertaken to
determine whether these negative impacts
of MSP on respiratory health persisted into
adolescence and if so whether these effects
acted through any or all of reduced lung
function; altered immune function,
characterized by modified or blunted
cytokine responsiveness at age 14; or
enhanced atopy.
Methods
Study Subjects
Adolescents participating in the 14-year
follow-up of the Raine Cohort (19) were
studied. The cohort initially consisted of
2,860 live births and has been followed
at birth, 1, 2, 3, 6, 8, 10, and 14 year of age
and was recruited to participate in
a randomized control trial of fetal
monitoring. The prenatal study did not
include any questions related to asthma or
allergies or any childhood diseases, and no
factors relevant to these were used to select
the women for the study (see the online
supplement for cohort description and
Tables E1 and E2 in the online supplement).
All aspects of the current study were
approved by our institutional review board
and parents gave written consent, with
assent obtained from the teenagers. The
antenatal questionnaire completed on
enrolment at 16- to 18-week gestation asked
about personal smoking and was used to
assign MSP status to the adolescents. The
reported smoking status indicated good
agreement with serum cotinine on a random
sample of the cohort (16).
Clinical and Immunologic
Phenotyping at Age 14
Current asthma (17, 20) was defined as
wheeze in the last 12 months in children
with a doctor diagnosis of asthma ever.
Children with current asthma who were
using asthma medication were defined
as having “medicated current asthma.”
Spirometry was performed as described
previously (18) according to American
Thoracic Society guidelines. BHR was
considered positive if FEV1 fell by at least
20% on a standard methacholine challenge
(17, 18).
Total IgE and specific IgE and IgG4 to
a panel of allergens were measured in serum
collected at age 6 and age 14 by
ImmunoCAP (Phadia AB, Uppsala,
Sweden); the panel of allergens comprised
HDM (Dermatophagoides pteronyssinus),
rye grass pollen (rye; Lolium perenne), cat,
couch grass (Cynodon dactylon), mold
mix (Penicillium notatum, Cladosporium
herbarum, Aspergillus fumigatus, Candida
albicans, Alternaria alternata,
Helminthosporium halodes), peanut, and
food mix (egg white, milk, fish, wheat,
peanut and soybean). Subjects were
considered atopic if they had specific IgE
greater than or equal to 0.35 kU/L for any
of these allergens and/or total IgE greater
than 300 kU/L (18).
Peripheral blood mononuclear cells
were cultured (18) stimulated with HDM,
rye, phytohemagglutinnin, and LPS with
and without IFN-g, or poly(I:C). Cytokine
proteins were measured by time-resolved
fluorometry (IL-5, IL-10, IL-12, IL-13, IFN-
g, and tumor necrosis factor-a) or mRNAs
were measured by quantitative reverse-
transcriptase polymerase chain reaction
(IL-4 and IL-9). Cytokine production above
unstimulated control (delta) was calculated
and used in analyses.
The mast cell and eosinophil products
prostaglandin F2a and eosinophil protein X
were measured from urine and normalized
against creatinine using ELISA (Cayman
Chemical, Ann Arbor, MI; Phadia AB).
Soluble CD14 was measured in plasma by
ELISA (BioScientific, Gymea, Australia).
Statistics
The groups of clinical and immunologic
variables used in the analyses are shown in
Figure 1. The effects of MSP on clinical and
respiratory outcomes were determined
using chi-square or Mann-Whitney U tests
as appropriate. Associations between
MSP and binary clinical outcomes were
examined using logistic regression. Because
of the large number of immunologic
measures, we summarized each set
(antibodies, inflammatory markers,
adaptive and innate stimuli responses)
using the treelet transform (21) into three
components per set and examined the
associations of each and all of these with
MSP and with respiratory outcomes using
regression analyses. Because this method
of examining possible mediation effects can
be subject to various biases from both
measured and unmeasured confounders
(22), we further examined whether
MSP acted through poor lung function
by restricting analyses to those with
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appropriate lung function. We also
assumed that if there was no association
between MSP and an intermediate variable
or set of variables we would not further
examine pathways through that set.
Continuous variables were log10-
transformed except for maternal BMI,
FEV1/FVC, and forced expiratory flow
midexpiratory phase (FEF25–75%)/FVC.
Handling of confounders and possible
mediation pathways is described in the
online supplement.
Results
Results from questionnaires, lung function
tests, and immunologic assays were available
for 1,129 subjects seen at 14 years of age
and comprise the study sample. MSP was
reported for 21.0% (237 of 1,129) of the
adolescents. MSP was strongly correlated
with post-natal environmental tobacco
smoke (ETS) exposure (see Table E3) and
all MSP-positive subjects also had post-
natal exposure to ETS. Ninety-two (8.1%)
of the teenagers reported current smoking.
One hundred and ten subjects (9.7%)
fulfilled the definition of medicated current
asthma and 124 (11.0%) had current
asthma; 141 (12.5%) had current wheeze
and 197 (17.4%) were positive for BHR.
The prevalence of respiratory and allergic
conditions at age 14 is shown in Table 1.
Asthma (medicated current asthma, P =
0.029 and current asthma, P = 0.002) and
current wheeze (P = 0.006) were more
common among MSP-positive teenagers
but BHR was not (P = 0.37). MSP-positive
subjects also reported more exercise-
induced wheeze (P , 0.001) and more had
lower lung function (FEV1/FVC , 80%;
P = 0.004), whereas the prevalence of atopy
(P = 0.59) was not increased. Current
smokers were excluded from further
analyses because adjustment for current
smoking would likely introduce bias
because of its being on most postulated
pathways from MSP (with odds ratio [OR]
for current smoking from MSP of 3.2; 95%
confidence interval [CI], 2.1–5.0) to
respiratory outcomes. With (and also
without, data not shown) adjustment for
maternal asthma and maternal
prepregnancy BMI (Table 2), MSP was
a risk factor for current asthma (1.84
[1.16–2.92]; P = 0.01), current wheeze (1.77
[1.14–2.75]; P = 0.011), exercise-induced
wheeze (2.29 [1.37–3.85]; P , 0.002), and
poor lung function (2.00 [1.24–3.34]; P =
0.005). Differing effects of MSP by sex,
maternal asthma status, and atopy were
examined using interaction terms and none
were significant (P . 0.15 in each analysis).
MSP was associated with reduced lung
function at age 14, including indices
reflecting airway size and function,
including lower FEF25–75% (P = 0.016),
lower FEV1/FVC (P = 0.009), and
FEF25–75%/FVC (P = 0.006) (Table 3).
Few immunologic measures differed
between MSP-positive and MSP-negative
subjects (see Tables E4–E7). Total IgE titers
were lower with MSP (geometric mean 61.1
vs. 74.0 kU/L; P = 0.05), as were titers of
HDM-IgG4 (geometric mean 4.5 vs. 6.3
kU/L; P = 0.03) and Couch grass-IgG4
(geometric mean 0.01 vs. 0.05 kU/L; P ,
0.01). In contrast, the number of peripheral
circulating neutrophils (geometric mean 3.0
vs. 2.8 3 109; P = 0.05) and basophils
(geometric mean 0.03 vs. 0.02 3 109; P =
0.01) was higher with MSP.
To examine whether the association of
MSP with asthma outcomes was through
a lung function pathway, models in Table 2
were reestimated including FEV1/FVC % as
an added explanatory variable (Table 4).
There was only slight attenuation of the
effects, indicating that MSP was unlikely
to be acting solely through poorer lung
function. Similar models including the
major components from the treelet analyses
of antibodies and inflammatory markers
showed similar or slighter changes
(Table 4). When analyses were done
separately in participants with poor or
adequate lung function, MSP effects were
slightly weaker in those with good lung
function (Table 4, Model 4) and stronger in
those with poor lung function (data not
shown). The lack of association between
MSP and cytokine responses precluded
examination of those pathways.
Discussion
MSP is a well-recognized risk factor for
respiratory disease in children, but the
precise mechanisms are largely speculative.
The results of the present study confirm that
this association persists into adolescence.
Although MSP was associated with lower
lung function, diminished lung function did
not account for the increased risks for
asthma and wheeze associated with MSP.
We have previously reported that
children in this cohort born to mothers who
smoked during pregnancy had a less mature
immune system at birth, as judged from
detectable levels of cytokines in cord blood,
and that this was associated with an
increased risk of asthma and atopy at 6 years
of age (12). We had anticipated that MSP
may increase asthma risk in adolescents
by increasing allergic sensitization and
enhancing allergy-related immune
responses, independent of any effects on
lung function. However, our data do not
support this hypothesis. We saw little
evidence of a less mature or reduced
immune response in the present study.
Total IgE and allergen-specific IgE
and IgG4 levels tended to be lower with
MSP, but most did not differ significantly
between groups (see Table E4). The
increased risks for asthma and wheeze
associated with MSP seemed to be
independent of adolescent immune
function (Table 4). From the broad panel
of adaptive and innate immune responses
that we have measured in the current study,
the only cytokine response that differed
significantly according to MSP status was
Figure 1. Matrix of variables examined in this study of the Western Australian Pregnancy (Raine)
Cohort at age 14 years. HDM = house dust mite; PHA = phytohemagglutinin.
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IL-12 induced by LPS1IFN-g, which was
significantly lower with MSP. We have
previously reported in this cohort that,
among those individuals sensitized to
HDM, IL-12 production reduces the risk of
asthma and reduces asthma severity (18).
Human in vitro studies (23) have shown
that nicotine exposure affected dendritic
cell maturation leading to reduced IL-12
production and activation of Th1 immune
responses, an effect that was overcome
only when environmental stimuli strongly
supported a Th1 rather than Th2 response.
Within our current study, IL-12 response
did not modify risk for any of the outcomes
examined. Thus, although it is possible that
MSP and subsequent post-natal smoke
exposure may directly reduce the capacity
for IL-12 production, particularly in
subjects with atopy characterized by high
production of Th2 cytokines, our study
does not suggest that MSP increases the
risk for respiratory disorders via altered
immune function in an unselected cohort
of adolescents. We have previously reported
that the timing of allergic sensitization is
critical in increasing asthma risk associated
with viral lower respiratory infections in
early life (24, 25), in that the increased
risk from lower respiratory infections in
early life were only seen in those with
contemporaneous allergic sensitization. No
increased risk was seen in subjects who
developed allergic sensitization later in life.
Thus, although there is no influence of MSP
on allergic sensitization or on allergy-
related immune responses in adolescents,
this does not preclude this pathway being
important in the first few years of life.
Although several previous studies have
observed that deficient immune function in
neonates or infants is linked to MSP or
parental smoking in early life (12, 14, 15),
to our knowledge only one has addressed
whether this impaired immune function
persists into late childhood (26). Tebow and
coworkers (26) examined the relationship
between parental smoking after pregnancy
and peripheral blood mononuclear cells
production of IFN-g and IL-4 in response
to mitogens concavalin A and phorbol
myristate acetate in 512 participants in the
Tucson Children’s Respiratory Study, who
had been followed from the neonatal period
until age 10 years. Dose–response
relationships were observed between
Table 2: Associations between Maternal Smoking during Pregnancy and Respiratory
Conditions at Age 14, Nonsmokers Only, Adjusted for Maternal Prepregnancy Body
Mass Index and Maternal Asthma
Outcome N n OR (95% CI) P Value
Medicated current asthma* 898 99 1.49 (0.91–2.45) 0.11
Current asthma† 869 111 1.84 (1.16–2.92) 0.010
Current wheeze 854 126 1.77 (1.14–2.75) 0.011
Exercise-induced wheeze 899 80 2.29 (1.37–3.85) 0.002
Poor lung function‡ 918 64 2.00 (1.14–3.50) 0.015
BHRx 807 175 1.31 (0.88–1.96) 0.18
Atopyjj 384 597 0.99 (0.71–1.37) 0.93
Definition of abbreviations: BHR = bronchial hyperresponsiveness; CI = confidence interval; N = total
subjects included in logistic regression; n = subjects in regression with clinical outcome; OR = odds
ratio.
*Medicated current asthma: asthma medication and wheeze in the past 12 months plus a doctor
diagnosis of asthma ever.
†Current asthma: wheeze in the past 12 months plus a doctor diagnosis of asthma ever.
‡Poor lung function was defined as FEV1/FVC less than 80%.xBHR defined as FEV1 fall of at least 20% with methacholine challenge.jjAtopy defined as total IgE greater than 300 kU/L or specific IgE greater than or equal to 0.35 kU/L for
any of seven allergens.
Table 1: Prevalence of Respiratory Conditions and Atopy among 14-Year-Olds Stratified by Maternal Smoking in Pregnancy
Condition
Whole Population (n = 1,129) Nonsmokers (n = 1,037)
MSP Pos N (%) MSP Neg N (%) P Value MSP Pos N (%) MSP Neg N (%) P Value
Medicated current asthma* (n = 110) Yes 32 (13.9) 78 (9.0) 0.029 27 (14.1) 72 (8.9) 0.031
No 199 790 164 734
Current asthma† (n = 124) Yes 39 (16.9) 85 (9.8) 0.002 34 (17.8) 78 (9.7) 0.001
No 192 783 157 728
Current wheeze (n = 141) Yes 42 (18.2) 99 (11.4) 0.006 37 (19.4) 90 (11.2) 0.002
No 189 769 154 716
Exercise-induced wheeze (n = 89) Yes 33 (14.3) 56 (6.5) ,0.001 28 (14.7) 53 (6.6) ,0.001
No 198 811 163 752
Poor lung function‡ (n = 77) Yes 26 (11.0) 51 (5.7) 0.004 21 (10.8) 46 (5.6) 0.008
No 211 841 173 782
BHR (n = 197) Yes 46 (19.4) 151 (16.9) 0.37 41 (21.1) 140 (16.9) 0.17
No 191 741 153 688
Atopy (n = 677) Yes 138 (58.5) 539 (60.4) 0.59 115 (59.6) 506 (61.1) 0.67
No 98 353 78 322
Definition of abbreviations: BHR = bronchial hyperresponsiveness; MSP = maternal smoking during pregnancy.
Table shows numbers of subjects with and without conditions; prevalence was compared between MSP-positive (MSP Pos) and MSP-negative
(MSP Neg) groups for each condition by chi-square test.
*Medicated current asthma: wheeze and asthma medication in last 12 months and doctor diagnosis of asthma ever.
†Current asthma: wheeze in last 12 months and doctor diagnosis of asthma ever.
‡Poor lung function was defined as FEV1/FVC less than 80%.
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parental smoking post-pregnancy
(cumulative pack-years) and the risk of
impaired IFN-g responses in the child
regardless of whether the mother smoked
in pregnancy. In the present study we did
not find reductions in allergen or mitogen-
induced cytokine responses with MSP, with
the exception of the IL-12 response referred
to earlier, which, given the number of
comparisons, may have been caused by
chance.
The literature is divided on whether
MSP or post-natal ETS exposure modifies
risk for atopy in children, with different
studies finding that smoke exposure
increased risk (27–29), decreased risk (30,
31), or did not modify risk (32, 33). In some
studies parental smoking only modified risk
for atopy after stratification by maternal
atopy (27, 28). In the present study we did
not find an association between MSP and
atopy at age 14 in the entire cohort or after
stratification for either maternal history or
atopy or asthma. Our results suggest that
MSP does not increase risk for current
respiratory disorders in adolescence
through increasing allergic sensitization.
Numerous studies have found that
MSP and/or post-natal tobacco smoke
exposure affects lung development, resulting
in diminished lung function in childhood
(34, 35). A previous report on the Raine
cohort (16) demonstrated lower lung
function at birth, as measured by peak tidal
expiratory flow as a proportion of
expiratory time, associated with MSP, with
a significant dose–response found between
peak tidal expiratory flow as a proportion of
expiratory time and the daily number of
cigarettes smoked. The data from the
present study demonstrate lower lung
function in adolescents born
to mothers who smoked during pregnancy.
When examining lung function as
a continuous variable, we found MSP
effects on indices of airway caliber and
function. FEF25–75%, expressed as %
predicted, was lower in the MSP group,
especially when current smokers were
excluded from the analysis (Table 3). In
addition, we found both lower volume-
corrected airway caliber, as judged from
FEF25–75%/FVC (36–39) and more airway
obstruction, as judged from a lower FEV1/
FVC ratio, with MSP. Fetal exposure to
nicotine via active placental transport has
been shown in animal models to negatively
affect lung and airway development,
reducing surface complexity of the lung
parenchyma, increasing collagen deposition
in large and small airways, up-regulating
surfactant protein gene expression, and
inducing neuroendocrine cell hyperplasia
Table 4: Associations between Maternal Smoking during Pregnancy and Respiratory Conditions at Age 14, Nonsmokers Only,
Adjusted for Maternal Prepregnancy Body Mass Index, Maternal Asthma, and Possible Intermediate Variables
Model 1 Model 2 Model 3 Model 4
Outcome OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Medicated current
asthma*
1.49 (0.91–2.45) 0.11 1.43 (0.87–2.36) 0.16 1.49 (0.88–2.55) 0.14 1.34 (0.77–2.31) 0.303
Current asthma† 1.84 (1.16–2.92) 0.010 1.76 (1.10–2.80) 0.018 1.77 (1.08–2.90) 0.024 1.74 (1.05–2.86) 0.030
Current wheeze 1.77 (1.14–2.75) 0.011 1.70 (1.09–2.65) 0.020 1.74 (1.08–2.79) 0.022 1.68 (1.05–2.71) 0.031
Exercise-induced
wheeze
2.29 (1.37–3.85) 0.002 2.20 (1.31–3.70) 0.003 2.37 (1.37–4.09) 0.002 2.05 (1.17–3.59) 0.012
Definition of abbreviations: CI = confidence interval; OR = odds ratio.
Model 1: same as Table 2; Model 2: Model 1 plus FEV1/FVC%; Model 3: Model 2 plus antibody components plus inflammatory marker components;
Model 4: Model 1 restricted to participants with good lung function, defined as FEV1/FVC greater than or equal to 80%.
*Medicated current asthma: asthma medication and wheeze in the past 12 months plus a doctor diagnosis of asthma ever.
†Current asthma: wheeze in the past 12 months plus a doctor diagnosis of asthma ever.
Table 3: Lung Function, Reported as % Predicted, Stratified by Maternal Smoking during Pregnancy Status in the Total Population
and in Nonsmokers Alone
Measure MSP
Total Population (n = 1,129) Nonsmokers (n = 1,022)
N Mean (SEM) Mean Rank P Value N Mean (SEM) Mean Rank P Value
% Predicted FEV1 Negative 889 96.3 (0.41) 561 0.598 825 96.4 (0.43) 511 0.774
Positive 237 96.9 (0.84) 573 194 96.1 (0.93) 505
% Predicted FVC Negative 889 92.0 (0.41) 552 0.018 825 92.0 (0.42) 503 0.114
Positive 237 94.3 (0.84) 608 194 93.7 (0.93) 540
%Predicted FEF25-75% Negative 889 99.6 (0.70) 572 0.056 825 99.6 (0.72) 519 0.016
Positive 237 96.7 (1.33) 526 194 95.6 (1.48) 463
FEV1/FVC, % Negative 892 91.6 (0.22) 578 0.007 828 91.6 (0.22) 523 0.009
Positive 237 90.1 (0.49) 514 194 89.9 (0.54) 461
FEF25-75%/FVC, % Negative 892 1.10 (0.01) 579 0.006 828 1.10 (0.01) 524 0.006
Positive 237 1.05 (0.02) 513 194 1.05 (0.02) 459
Definition of abbreviations: FEF25-75% = forced expiratory flow midexpiratory phase; MSP = maternal smoking during pregnancy; N = subjects in analysis.
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(7, 40). We were not able to examine
separately the effects of prenatal and post-
natal tobacco smoke exposure because of
the high correlation between MSP and
post-natal ETS exposure; all MSP-positive
subjects also had post-natal ETS exposure
(see Table E3). Most studies, including the
present one, have difficulty in separating
potential effects of prenatal from post-natal
tobacco smoke exposure. The literature is
unclear on whether prenatal or post-natal
smoke exposure confers the most risk for
asthma and associated respiratory disorders
(41–45). A metaanalysis examining the
effects of childhood ETS exposure on
asthma development found that duration of
exposure seems to be an important risk
factor that has been underestimated by
previous studies and metaanalyses (46).
Unfortunately, we are not able to contribute
definitive data to this debate from the
present study.
One mechanism proposed in the
literature for how tobacco smoke exposure
increases the risk of respiratory diseases,
including asthma, is via epigenetic
modification of gene expression (47, 48).
Epigenetics are presumed to underlie the
observation of increased asthma in children
whose maternal grandmother smoked
during the mother’s gestation (49).
Although the effect was stronger if the
mother smoked during the child’s gestation
a significant effect was also seen in children
born to mothers who do not smoke (49).
An increase in global DNA methylation
and increased methylation of promoter
CpG islands has been reported in children
born to mothers who smoked during
pregnancy (8). We did not study gene
methylation in the present study and
cannot comment on any potential
epigenetic effects on lung function
because we did not study lung tissue.
However, the lack of persistent effect of
MSP on immune responses suggests that
even if epigenetic effects were responsible
for the effects on immune maturation we
reported previously (12), they are not
likely to be involved in conveying asthma
risk in the teenagers studied.
MSP was associated with an increased
risk for asthma and wheeze outcomes and
lower lung function in the present study.
Although MSP was strongly associated with
low lung function, the adjusted analyses
(Table 4) show that the effects of MSP on
lung function do not account for the MSP-
associated increase in asthma risk in
adolescents. Both MSP and a reduction
in FEV1/FVC ratio were independent risk
modifiers for current asthma, current
wheeze, and exercise-induced wheeze.
Because there are no major effects of MSP
on atopy or asthma-related immune
responses, immunologic mechanisms
are unlikely to be responsible for the
independent increase in asthma risk from
MSP. We must point out that although
MSP effects on immune mechanisms are
not responsible for the MSP effect on
increasing asthma risk, this does not
mean that immune factors impose no risk
for asthma in adolescents. On the contrary,
the usual “immune suspects” including
allergen-specific IgE, markers of
eosinophilic inflammation, and allergy-
associated cytokine profiles are risk factors
for asthma during adolescence in the Raine
cohort (18).
In summary, MSP and subsequent
exposure to ETS is associated with lower
lung function and an independent increased
risk of asthma that persists into adolescence.
There was no effect of MSP on allergic
sensitization or asthma-associated immune
responses. Primary prevention of asthma
and related respiratory conditions must
include efforts to prevent MSP and post-
natal ETS exposure. n
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